Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors

NCT ID: NCT05367778

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 176 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-03
• Study Completion Date: 2026-04-30

Brief Summary

HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.

Detailed Description

This is a phase 1/2, first-in-human, open-label, multicenter study of HS-10370, this study has two parts: phase 1 and phase 2. The phase 1 portion consists of dose escalation and dose expansion, which is aimed to assess the safety and tolerability of HS-10370 in subjects with advanced solid tumors and evaluate the preliminary efficacy of HS-10370. Phase 2 will be conducted to evaluate the efficacy of HS-10370 in subjects with locally advanced or metastatic NSCLC with a KRAS G12C mutation.

Conditions

Advanced Solid Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HS-10370（Phase 1a：Dose Escalation）

Subjects with advanced solid tumors will be enrolled in dose escalation cohorts. Dose escalation of HS-10370 will be done to determine maximum tolerated dose.

Group Type: EXPERIMENTAL

HS-10370

Intervention Type: DRUG

HS-10370 will be administered orally once daily in a continuous regimen

HS-10370（Phase 1b：Dose Expansion ）

Depending on data obtained from the dose escalation part, dose expansion may proceed with multiple cohorts in subjects with advanced solid tumors having a KRAS G12C mutation.

Group Type: EXPERIMENTAL

HS-10370

Intervention Type: DRUG

HS-10370 will be administered orally once daily in a continuous regimen

HS-10370（Phase 2 ）

Subjects with locally advanced or metastatic KRAS G12C mutant NSCLC will be enrolled in phase 2 part to evaluate the efficacy and sufficient safety of HS-10370 as monotherapy.

Group Type: EXPERIMENTAL

HS-10370

Intervention Type: DRUG

HS-10370 will be administered orally once daily in a continuous regimen

Interventions

HS-10370

HS-10370 will be administered orally once daily in a continuous regimen

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Men or women greater than or equal to 18 years

2. Locally advanced or metastatic cancer patients confirmed by histology or cytology, for which standard treatment is invalid, unavailable or intolerable

3. Pathological, tumor tissue samples can be used to test KRAS G12C mutation by central laboratory for Phase 1b subjects.

4. At least one measurable lesion in accordance with RECIST 1.1

5. Eastern Cooperative Oncology Group (ECOG) performance status: 0~1

6. Estimated life expectancy >12 weeks

7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.

8. Females must have the evidence of non-childbearing potential

9. Signed and dated Informed Consent Form

Exclusion Criteria

1. Treatment with any of the following:

1. Previous or current treatment with KRAS G12C inhibitors

2. Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of HS-10370

3. Any investigational agents and large molecule antibodies within 28 days of the first dose of HS-10370

4. Local radiotherapy for palliation within 2 weeks of the first dose of HS-10370, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose of HS-10370

5. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of HS-10370

2. Inadequate bone marrow reserve or serious organ dysfunction

3. Uncontrolled pleural, ascites or pericardial effusion

4. Known and untreated, or active central nervous system metastases

5. Active autoimmune diseases or active infectious disease

6. Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications

7. History of hypersensitivity to any active or inactive ingredient of HS-10370 or to drugs with a similar chemical structure or drugs belonging to the same category of HS-10370

8. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator

9. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator

10. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study

11. History of neuropathy or mental disorders, including epilepsy and dementia

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xiaorong Dong, PhD

Role: PRINCIPAL_INVESTIGATOR

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Locations

Union Hospital Tong Ji Medical College, HuaZhong University of Science and Technology

Wuhan, Hubei, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiaorong Dong, PhD

Role: CONTACT

xhzzdxr@126.com

13986252286

Facility Contacts

Xiaorong Dong, PhD

Role: primary

xhzzdxr@126.com

13986252286

Other Identifiers

HS-10370-101

Identifier Type: -

Identifier Source: org_study_id